Trial Profile
An open label,randomised study to evaluate the efficacy and safety of dual-therapy [lopinavir and ritonavir plus lamivudine in Chinese ART-naïve HIV-infected patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Sep 2017
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary) ; Lopinavir/ritonavir (Primary) ; Efavirenz; Tenofovir
- Indications HIV infections
- Focus Therapeutic Use
- 01 Sep 2017 New trial record
- 26 Jul 2017 Primary endpoint (Proportions of the patients with plasma HIV-RNA 50 copies/mL at week 48) has been met , as per results presented at the 9th International AIDS Society Conference on HIV Science.
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science